Xeroderma pigmentosum

LAST UPDATED: Aug 02, 2021

Introduction

Xeroderma pigmentosum (XP) is a rare autosomal recessive disease characterised by photosensitivity, pigmentary changes, premature skin ageing, neoplasia and abnormal DNA repair.

This chapter is set out as follows:


History

  • XP affects males and females equally
  • The skin is normal at birth
  • The first skin changes are noticed between the sixth month and third year in over 75% of cases, but may appear in later childhood
  • Most cases beginning in childhood have reached the tumour stage by the age of 20 years, but it can arise as early as four years
  • Photophobia and conjunctivitis are common features
  • Neurological abnormalities occur in approximately 20% of cases

Clinical findings

  • Freckling and dryness on UV-exposed sites
  • Acute sunburn or persistent erythema
  • Actinic keratoses, SCC and BCC are all common and present in large numbers
  • Melanomas arise and may be multiple

Clinical Images

Please refer to notes on image rights at bottom of the page with regards to individual image ownership.


Investigations

  • The condition is usually diagnosed from a young age
  • Testing the DNA repair factor from a blood or skin sample is conclusive

Management

  • Genetic counselling is also needed - parents who have a child with XP have a one in four chance of having another affected child

Other resources


Disclaimer - the author PCDS cannot accept responsibility for any misleading or incorrect statements, and the management of individual patients remains the direct responsibility of the individual doctor. We do however hope that visitors to this site can contact us regarding comments that are considered misleading or incorrect so that we can continue to improve the site.

Image Rights - The PCDS would like to thank Dermatoweb, DermQuest (Galderma), and others who have contributed images. All named individuals and organisations maintain copyright for the relevant images.

Quick Links

The following pharmaceutical companies have had no involvement in the content of this website or in our conference programmes

Almirall
Galderma
Glenmark
Johnson & Johnson
La Roche-Posay
LEO Pharma
Pierre Fabre
Schuco